Table 1.
Clinical and demographics, neuropsychological results.
| Clinical and demographic features | Pre-ECT mean (SD) | Post-ECT mean (SD) | t-Statistic (p-value) |
|---|---|---|---|
| Age +/− SD (years) | 64.2 (7.9) | ||
| Sex: Male/Female | 12/17 | ||
| Race: White/Black/Asian | 27/1/1 | ||
| Ethnicity: Non-Hispanic/Hispanic | 24/5 | ||
| Single episode/recurrent | 1/28 | ||
| Psychotic/non-psychotic | 5/24 | ||
| Episode duration (months) | 44.4 (59.0) | ||
| Number of episodes | 4.3 (3.0) | ||
| Age of onset (years) | 28.8 (17.1) | ||
| Lifetime duration (years) | 17.2 (16.2) | ||
| ECT appropriateness scale | 8.5 (1.4) | ||
| Maudsley treatment failure | 2.4 (1.3) | ||
| Educationa | 5.8 (1.7) | ||
| Antidepressants: SSRI/SNRI/TCA/NDRI/NaSSA/SMSb | 7/12/3/2/2/3 | ||
| Antipsychotics/Mood Stabilizers/Benzodiazepines | 14/0/10 | ||
| Amplitude-determined seizure, Ebrain, seizure duration | |||
| Amplitude-determined seizure (milliampere) | 312.3 (112.9) | ||
| Ebrain (Volts/meter per milliampere) | 0.15 (0.02) | ||
| EEG seizure duration titration (seconds) | 42.5 (38.8) | ||
| EEG seizure duration 800 mA (seconds) | 38.9 (18.8) | ||
| RUL treatment number | 8.1 (2.8) | ||
| Depression assessment | |||
| Inventory of depressive symptoms – clinician rated | 48.5 (10.0) | 27.3 (16.1) | 6.6 (<0.001) |
| Cognitive assessments | |||
| Montreal cognitive assessment | 23.9 (3.8) | ||
| Test of premorbid functioning standard score total | 108.6 (13.9) | ||
| Delis Kaplan executive function system | |||
| Letter fluency scaled score | 8.8 (3.8) | 7.9 (4.0) | 2.4 (0.03) |
| Category fluency scaled score | 9.2 (4.6) | 7.7 (3.9) | 2.7 (0.01) |
| Category switching total switching accuracy scaled score | 8.6 (4.1) | 8.3 (3.8) | 0.4 (0.66) |
| Color-word interference condition 2 scaled score | 9.3 (3.1) | 8.3 (3.8) | 2.2 (0.04) |
| Color-word interference condition 3 scaled score | 9.1 (3.1) | 7.9 (4.3) | 1.4 (0.18) |
| Tower total achievement scaled score | 9.65 (3.0) | 10.1 (3.0) | −0.8 (0.46) |
| California verbal learning test -3rd edition | |||
| Trial 1 free recall correct standard score | 4.4 (1.4) | 10.7 (3.4) | −11.3 (<0.001) |
| Long delay free recall correct standard score | 7.9 (3.4) | 8.8 (3.6) | −1.7 (0.11) |
| Total recall correct sum of scaled scores | 55.9 (20.0) | 63.2 (19.6) | −2.5 (0.02) |
| Standard score summary – trials I – 4 correct sum of scaled scores | 32.3 (12.3) | 37.9 (10.9) | −3.1 (0.005) |
| Delayed recall correct sum of scaled scores | 23.6 (9.3) | 25.3 (10.1) | −1.2 (0.23) |
| Dot counting test | |||
| Mean ungrouped time (seconds) | 7.3 (2.0) | 8.7 (3.1) | −2.6 (0.01) |
| Mean grouped time (seconds) | 3.2 (2.6) | 2.6 (1.2) | 2.3 (0.03) |
| E-score | 11.5 (3.6) | 12.6 (4.0) | −1.4 (0.17) |
| Wechsler adult intelligence scale IV digit span scaled score | 10.4 (3.3) | 10.0 (1.9) | 0.8 (0.39) |
aEducation, 1 = grade 6 or less, 2 = grade 7–12, 3 = graduated high school, 4 = part college or university, 5 = graduated 2-year college, 6 = graduated 4-year college, 7 = part graduate or professional school, 8 = completed graduate or professional school.
bSSRI select serotonin reuptake inhibitor, SNRI serotonin-norepinephrine reuptake inhibitor, TCA tricyclic antidepressant, NDRI norepinephrine-dopamine reuptake inhibitor, NaSSA noradrenergic and specific serotonergic antidepressant, SMS serotonin modulator and stimulator.